Vinblastine, sold under the brand name Velban among others, is a chemotherapy medication, typically used with other medications, to treat a number of types of cancer. This includes Hodgkin's lymphoma, non-small-cell lung cancer, bladder cancer, brain cancer and other malignancies where antimitotic therapy is indicated. It is a natural vinca alkaloid derived from Catharanthus roseus and is administered intravenously as part of combination regimens; it is a vesicant and must not be given intrathecally. Vinblastine exhibits multi compartment pharmacokinetics with extensive tissue distribution and predominantly hepatic metabolism mediated by cytochrome P450 3A isoforms, followed by biliary excretion. Clinically relevant effects include dose dependent myelosuppression with neutropenia as the principal toxicity, with less pronounced peripheral neurotoxicity compared with some other vinca alkaloids. Important clinical considerations include adjustment or delay for marrow suppression, monitoring for drug interactions that inhibit CYP3A4 which can increase exposure, and use of validated HPLC or LC-MS assays for potency and impurity assessment during manufacturing and quality control.
Parent: Vinblastine Sulfate
Parent: Vincristine / Vinblastine
Typical active pharmaceutical ingredient specifications for vinblastine list known related substances and limits to control potential process and degradation products; representative acceptable limits are vincristine up to 0.5 percent relative to vinblastine, desacetylvinblastine up to 0.2 percent, catharanthine up to 0.1 percent, vindoline up to 0.1 percent, leurosine up to 0.1 percent, with total related compounds and impurities commonly limited to no more than 1.0 percent by weight. Individual unspecified impurities are typically reported when exceeding about 0.05 percent and qualified following ICH Q3A and Q3B principles, with assay acceptance ranges for the drug substance generally in the 95.0 to 105.0 percent range on a dry basis. Identification and quantification are performed using stability indicating HPLC methods with orthogonal confirmation by LC-MS for structural characterization.
No, Vinblastine is not an antibiotic. It is a plant derived chemotherapeutic vinca alkaloid that interferes with cell division and is used to treat various cancers.
Vinblastine binds to tubulin heterodimers and inhibits microtubule polymerization, disrupting mitotic spindle formation, causing cell cycle arrest in metaphase and leading to apoptotic cell death in rapidly dividing cells.
Both vincristine and vinblastine belong to the vinca alkaloid class of antimitotic chemotherapeutic agents, also categorized broadly as plant derived microtubule inhibitors or antineoplastic alkaloids.
Vincristine and vinblastine are structurally related vinca alkaloids with overlapping mechanisms but different clinical and toxicity profiles. Vincristine tends to cause more peripheral neurotoxicity and is often dose limited by neuropathy, while vinblastine produces more pronounced myelosuppression, particularly neutropenia. Clinical indications and dosing differ between the two agents and both require intravenous administration with careful handling due to vesicant properties.
